The overall goal is to establish the critical design features needed for engineer a new generation of targeted polymer-based combination therapies that displays a safety/efficacy profile for metastatic BC in a patient-personalised manner.
To do so, these aspects need to be taken into account:
Nanoconjugates will be precisely controlled in physico-chemical terms and bioresponsiveness related to specific biological environments.
A novel integrated experimental approach will be used including controlled polymerisation, supramolecular chemistry, patient-derived cell-based models and in vivo monitoring, using a reiterative design optimisation (not screening) to identify descriptors/biomarkers.
New strategies for the treatment and prevention of BC metastasis by inhibiting tumour-derived exosome release pathways will be implemented.